



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2003, OMB 0651-0031

Approved for use through 10/31/2012. GSA GS-1031  
Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Substitute for form 1449A/PTO**

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<b>Application Number</b>	10/612,138
<b>Filing Date</b>	July 2, 2003
<b>First Named Inventor</b>	Zhihua, S.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Not yet assigned
<b>Attorney Docket Number</b>	ORT-1643 US NP

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature	Baileys	Date Considered	6/23/05
-----------------------	---------	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kind of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

<b>Application Number</b>	10/612,138
<b>Filing Date</b>	July 2, 2003
<b>First Named Inventor</b>	Zhihua, S.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Not yet assigned
<b>Attorney Docket Number</b>	ORT-1643 US NP

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
BB		CLINTON, R.O. et al.: "Communications to the Editor. Steroidal [2,3-d]isoxazoles". Journal of Organic Chemistry, January (1961), 26, page 279. Sterling-Winthrop Research Institute, New York.	
	*	HIRSCHMANN, R. et al.: "Communications to the Editor. Synthesis and Structure of Steroidal 4-Pregneno[3,2-c] Pyrazoles. A Novel Class of Potent Anti-Inflammatory Steroids". Journal of American Chemical Society, (1993), 85, pages 120-122. Merck Sharp & Dohme, New Jersey.	
	*	CLINTON, R.O. et al.: "Communications to the Editor. Steroidal [3,2-c]Pyrazoles". Journal of American Chemical Society, (1959), 81, pages 1513-1514. Sterling-Winthrop Research Institute, New York.	
BB		ACKERMAN, J.H. et al.: "Steroidal Heterocycles. X. Steroidal[3,2d]pyrimidines and Related Compounds". Sterling-Winthrop Research Institute, New York, Journal of Medical Chemistry, Vol.7, (1964), pgs. 238-240.	
		ALBERT, J.L. et al.: "Estrogen Regulation of Placental Alkaline Phosphatase Gene Expression in a Human Endometrial Adenocarcinoma Cell Line". Cancer Research, (50), pgs. 3308-3310, June 1, 1990.	
		Allan, G.F. et al.: "An Ultrahigh-Throughput Screening Assay for Estrogen Receptor Ligands". Analytical Biochemistry Vol. 275, pgs. 243-247, (1999).	
		CLINTON, R.O. et al.: "Steroidal[3,2-c]pyrazoles. II. Androstanes, 19-Norandrostanes and their Unsaturated Analogs". Journal of American Chemical Society, (1961), 83, pgs. 1478-1491. Sterling Winthrop Research Institute, New York.	
		GUPTA, R. et al.: "Synthesis and Biological Activity of Azasteroidal [3,2-c] and [17,16-c]pyrazoles". European Journal of Medical Chemistry, (1996), 31, pgs. 241-247.	
		HIRSCHMANN, R. et al.: "Synthesis and Structure of Steroidal Pregn-4-eno-and 5 $\alpha$ -Pregnano [3,2-c]pyrazoles. A Novel class of Potent Anti-Inflammatory Steroids". Journal of American Chemical Society, (1964), 86, pgs. 1520-1527.	
		LAITONJAM, W.S. et al.: "Synthesis of some A- and D-ring Fused Steroidal Pyrazoles, Isoxazoles and Pyrimidines". Steroids (2002), 67, pgs. 203-209.	
		MANSON, A.J. et al.: "Steroidal Heterocycles. VII. Androstano[2,3-d]isoxazoles and Related Compounds". Journal of Medicinal Chemistry (1963) 6, no.1, pgs. 1-9.	
		RADU, I. et al.: "New Efficient Pathway for the Synthesis of 3-Aminoestrone". Tetrahedron Letters (2002), 43, pgs. 7617-7619.	
		ROTTLANDER, M. et al.: "Palladium-Catalyzed Cross-Coupling Reactions with Aryl Nonaflates: A Practical Alternative to Aryl Triflates" (1998), 63, pgs. 203-208.	
		WEIDNER, J.J. et al.: "Preparation of N-Aryl-2-hydroxypropionamides from Hydroxy Aromatic Compounds Using a One-Pot Smiles Rearrangement Procedure." Tetrahedron, (1987), 53, no.18, pgs.6303-6312.	
BB		WELSHONS, W.V.: "Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol". Breast Cancer Research and Treatment 10, (1987), pgs. 169-175.	
		ALBERT, J.L.: "Estrogen Regulation of Placental Alkaline Phosphatase Gene Expression in a Human Endometrial Adenocarcinoma Cell Line". Cancer Research 50, (1990) pgs. 3308-3310. <i>See above/under see</i>	
		ALLAN, G.F.: "An Ultrahigh-Throughput Screening Assay for Estrogen Receptor Ligands". Analytical Biochemistry 275, (1999), pgs. 243-247. <i>See above/under see</i>	
Examiner Signature	Baoduo	Date Considered	6/23/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*Copies not provided